Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Frederiksberg, Denmark Clinical Trials

A listing of Frederiksberg, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (32) clinical trials

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). Patients with advanced cancer are eligible if ...

Phase

2.14 miles

Learn More »

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

APO010 is a novel investigational antitumour agent. It is a recombinant form of human Fas ligand (FasL), a protein with the function of inducing programmed cell death (apoptosis). Preclinical studies indicate that multiple myeloma is sensitive for APO010. Estimation of DRP for APO010 in myeloma patients suggests that it may ...

Phase

2.14 miles

Learn More »

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

The primary objectives are to determine the safety and efficacy of oral larotrectinib in pediatric patients with advanced solid or primary central nervous system (CNS) tumors. The secondary objectives comprise e.g. the determination of the pharmacokinetic properties, the maximum tolerated dose/ recommended dose and the tumor-type specific efficacy of larotrectinib. ...

Phase

2.14 miles

Learn More »

Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer

The dose escalation part will occur in cervical cancer subjects who have progressed during or after standard of care therapy and who are intolerant or ineligible to receive standard of care treatments. Arm A will be conducted by escalating doses of both tisotumab vedotin and bevacizumab. Dose escalations of the ...

Phase

2.14 miles

Learn More »

Safety and Pharmacokinetics of ODM-209

Part 1: to evaluate the safety and tolerability of ODM-209, to define the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ODM-209, if feasible, to define the recommended dose of ODM-209 and replacement therapy for Part 2 of the study. Part 2: to further evaluate the safety and ...

Phase

2.14 miles

Learn More »

Safety Efficacy PD of FE203799 in Short Bowel Syndrome on Parenteral Support

This trial is divided into 2 parts. Part A of this trial is a repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and PD of FE 203799 in 8-10 patients with SBS. Additionally, the plasma concentration of FE 203799 will be assessed for determination of the ...

Phase

2.14 miles

Learn More »

Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency

This is a repeated dose, open label trial investigating safety, efficacy, PD and PK of FE 203799 in 8 patients with SBS . The patients will receive a subcutaneous (SC) dose of 5 mg FE 203799 once weekly for 4 consecutive weeks, and efficacy parameters and PK will be assessed ...

Phase

2.14 miles

Learn More »

Radiotherapy Delivery in Deep Inspiration for Pediatric Patients

Background The majority (approximately 80%) of pediatric patients with cancer become long-term survivors. Long-term follow-up of childhood cancer survivors has documented a substantial treatment-induced increased mortality and morbidity, primarily from cardiovascular disease and second cancers. Specifically, cardiac mortality has been shown to be 5-fold higher, cardiac morbidity 2-fold to 6-fold ...

Phase

2.14 miles

Learn More »

Phase I/II Study of Avelumab in Pediatric Cancer Subjects

This is a multi-center, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in pediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid tumors (including central nervous system tumors) and lymphoma for which no standard ...

Phase

2.14 miles

Learn More »

GEN3013 (DuoBody -CD3xCD20) Safety Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part (phase 1, first-in-human (FIH) and an expansion part phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Phase

2.14 miles

Learn More »